Search Results

You are looking at 71 - 80 of 508 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Ali Raza Khaki, V.K. Gadi, and Vinay Prasad

Multiple predictive assays have been implemented into clinical practice to help determe which women with early-stage hormone-sensitive breast cancer may benefit from adjuvant chemotherapy and which may not. These assays were originally developed as

Full access

Junmiao Wen and Donglai Chen

into 5 subgroups: surgery alone, surgery plus adjuvant chemotherapy with or without radiotherapy, neoadjuvant chemotherapy with or without radiotherapy plus surgery and adjuvant chemotherapy with or without radiotherapy, concurrent chemoradiotherapy

Full access

Shaneli A. Fernando and Stephen B. Edge

adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic

Full access

Rebecca P. Petersen and David H. Harpole Jr.

results . Clin Cancer Res 2005 ; 11 [ suppl 13 ]: 4984 – 4987 . 16. Kato H Ichinose Y Ohta M . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung . N Engl J Med 2004 ; 350 : 1713 – 1721

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

Full access

Scott M. Schuetze

sarcoma: eight-year experience with adjuvant chemotherapy . J Cancer Res Clin Oncol 1983 ; 106 ( suppl ): 55 – 67 . 16. Sutow WW Sullivan MP Fernbach DJ . Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology

Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Adjuvant Therapy for Stage II Disease The panel discussed the impact of adjuvant chemotherapy on

Full access

Lingling Du and Andrea Wang-Gillam

Neoadjuvant Approach Phase III trials have demonstrated a clear survival benefit with adjuvant chemotherapy. 5 , 7 Multiple studies examined neoadjuvant therapy as an alternative to the traditional adjuvant approach. Neoadjuvant therapy offers patients the

Full access

Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth

Background Adjuvant chemotherapy (ACT) with 5-fluorouracil (FU) has been the standard of care for stage III or high-risk stage II colon cancer since the 1990s. 1 This treatment is based on a series of randomized clinical trials (RCTs) showing

Full access

Robert E. Smith Jr.

:// . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy